WO2002102235A3 - Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer - Google Patents

Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer Download PDF

Info

Publication number
WO2002102235A3
WO2002102235A3 PCT/US2002/019297 US0219297W WO02102235A3 WO 2002102235 A3 WO2002102235 A3 WO 2002102235A3 US 0219297 W US0219297 W US 0219297W WO 02102235 A3 WO02102235 A3 WO 02102235A3
Authority
WO
WIPO (PCT)
Prior art keywords
ovarian cancer
methods
diagnosis
compositions
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/019297
Other languages
French (fr)
Other versions
WO2002102235A2 (en
Inventor
David H Mack
Kurt C Gish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EOS Biotechnology Inc
Original Assignee
EOS Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EOS Biotechnology Inc filed Critical EOS Biotechnology Inc
Priority to JP2003504826A priority Critical patent/JP2005508144A/en
Priority to EP02752063A priority patent/EP1517998A2/en
Priority to AU2002347428A priority patent/AU2002347428A1/en
Priority to CA002451465A priority patent/CA2451465A1/en
Priority to MXPA03011979A priority patent/MXPA03011979A/en
Publication of WO2002102235A2 publication Critical patent/WO2002102235A2/en
Anticipated expiration legal-status Critical
Publication of WO2002102235A3 publication Critical patent/WO2002102235A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Described herein are genes whose expression are up-regulated or down-regulated in ovarian cancer. Related methods and compositions that can be used for diagnosis and treatment of ovarian cancer are disclosed. Also described herein are methods that can be used to identify modulators of ovarian cancer.
PCT/US2002/019297 2001-06-18 2002-06-18 Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer Ceased WO2002102235A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2003504826A JP2005508144A (en) 2001-06-18 2002-06-18 Ovarian cancer diagnostic method, composition and method for screening ovarian cancer modulator
EP02752063A EP1517998A2 (en) 2001-06-18 2002-06-18 Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2002347428A AU2002347428A1 (en) 2001-06-18 2002-06-18 Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA002451465A CA2451465A1 (en) 2001-06-18 2002-06-18 Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
MXPA03011979A MXPA03011979A (en) 2001-06-18 2002-06-18 Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer.

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US29923401P 2001-06-18 2001-06-18
US60/299,234 2001-06-18
US31528701P 2001-08-27 2001-08-27
US60/315,287 2001-08-27
US31754401P 2001-09-05 2001-09-05
US60/317,544 2001-09-05
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US37224602P 2002-04-12 2002-04-12
US60/372,246 2002-04-12

Publications (2)

Publication Number Publication Date
WO2002102235A2 WO2002102235A2 (en) 2002-12-27
WO2002102235A3 true WO2002102235A3 (en) 2005-02-03

Family

ID=27540849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019297 Ceased WO2002102235A2 (en) 2001-06-18 2002-06-18 Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer

Country Status (6)

Country Link
EP (1) EP1517998A2 (en)
JP (1) JP2005508144A (en)
AU (1) AU2002347428A1 (en)
CA (1) CA2451465A1 (en)
MX (1) MXPA03011979A (en)
WO (1) WO2002102235A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840887B2 (en) 2007-09-26 2014-09-23 Genentech, Inc. Antibodies
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE413466T1 (en) 1998-09-02 2008-11-15 Diadexus Inc METHOD FOR THE DIAGNOSIS, ASSESSMENT AND IMAGING OF VARIOUS CANCER DISEASES
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
WO2004002514A1 (en) * 2002-06-26 2004-01-08 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
DE10230631A1 (en) * 2002-07-02 2004-01-22 Metagen Pharmaceuticals Gmbh Uses of Ngal-binding substances for the diagnosis and treatment of cancer
US7851213B2 (en) * 2002-07-03 2010-12-14 Sanofi Pasteur Limited Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
EP1575500A4 (en) 2002-07-12 2007-01-03 Univ Johns Hopkins MESOTHELIN VACCINES AND MODEL SYSTEMS
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
ATE494296T1 (en) * 2002-09-11 2011-01-15 Genentech Inc COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
CA2510315C (en) 2002-12-20 2014-01-28 Abbvie Biotherapeutics Inc. Antibodies against gpr64 and uses thereof
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
KR20120064120A (en) 2004-06-01 2012-06-18 제넨테크, 인크. Antibody drug conjugates and methods
WO2005118840A2 (en) * 2004-06-03 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10)
KR101270829B1 (en) 2004-09-23 2013-06-07 제넨테크, 인크. Cystein engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
AU2006321553B2 (en) 2005-12-08 2012-03-08 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
WO2007098102A2 (en) 2006-02-17 2007-08-30 Children's Medical Center Corporation Free ngal as a biomarker for cancer
HRP20150884T1 (en) 2006-03-21 2015-09-25 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
TWI596109B (en) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 Peptide vaccine for cancers exhibiting tumor-associated antigens
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2198306A1 (en) * 2007-09-06 2010-06-23 Case Western Reserve University Methods for diagnosing and treating cancers
CA2700860C (en) 2007-10-01 2016-07-19 Jonathan A. Terrett Human antibodies that bind mesothelin, and uses thereof
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
CN102159248B (en) 2008-07-15 2013-09-11 健泰科生物技术公司 Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
SG195571A1 (en) 2008-10-22 2013-12-30 Oncotherapy Science Inc Rab6kifl/kif20a epitope peptide and vaccines containing the same
KR20110084280A (en) 2008-11-03 2011-07-21 알레시아 바이오쎄라퓨틱스 인코포레이티드 Antibodies that specifically block the biological activity of tumor antigens
MY173526A (en) 2009-03-25 2020-01-31 Genentech Inc Novel anti-?5?1 antibodies and uses thereof
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
BR112012012750A2 (en) 2009-11-30 2020-08-11 Genentech Inc isolated antibody, cell, isolated nucleic acid and method
DK2528625T3 (en) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepines and their conjugates
BR112012030311A2 (en) 2010-06-08 2017-01-24 Genentech Inc antibody
EP3409287B9 (en) 2010-09-29 2021-07-21 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
JP5889912B2 (en) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド Alaninyl maytansinol antibody conjugate
PE20141114A1 (en) 2010-12-20 2014-09-15 Genentech Inc ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES
RS59080B1 (en) 2011-03-31 2019-09-30 Adc Therapeutics Sa Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
KR101992502B1 (en) 2011-05-12 2019-06-24 제넨테크, 인크. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
JP6104257B2 (en) 2011-10-14 2017-03-29 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
HRP20190946T1 (en) 2012-01-09 2019-07-26 Adc Therapeutics Sa MEDICINES FOR TREATMENT OF THREE-NEGATIVE BREAST CANCER
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
ES2649990T3 (en) 2012-10-12 2018-01-16 Medimmune Limited Anti-CD22-pyrrolobenzodiazepine antibody conjugates
CN104837502B (en) 2012-10-12 2018-08-10 麦迪穆有限责任公司 Pyrrolobenzodiazepines and their conjugates
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
EP2951592A4 (en) * 2013-01-31 2017-01-04 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Autoantibody signature for the early detection of ovarian cancer
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
SG11201507214SA (en) 2013-03-13 2015-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
NZ710746A (en) 2013-03-13 2018-11-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3033111B1 (en) 2013-08-12 2019-03-13 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
SI3055331T1 (en) 2013-10-11 2021-04-30 Oxford Bio Therapeutics Limited Conjugated antibodies against ly75 for the treatment of cancer
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
BR112016013258A2 (en) 2013-12-16 2018-01-16 Genentech Inc antibody-drug conjugate, pharmaceutical composition, method for treating cancer and kit
KR20170042495A (en) 2013-12-16 2017-04-19 제넨테크, 인크. Peptidomimetic compounds and antibody-drug conjugates thereof
JP6671292B2 (en) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド Peptidomimetic compounds and antibody-drug conjugates thereof
JP6531166B2 (en) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugate
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017003123A (en) 2014-09-12 2017-05-12 Genentech Inc Cysteine engineered antibodies and conjugates.
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
US20160074527A1 (en) 2014-09-17 2016-03-17 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
MX2017007169A (en) 2014-12-03 2018-05-02 Genentech Inc Quaternary amine compounds and antibody-drug conjugates thereof.
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CA2996902C (en) 2015-10-02 2020-06-02 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
PH12022551111A1 (en) 2015-10-05 2023-08-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
EP3362100B1 (en) 2015-10-16 2022-06-22 Genentech, Inc. Hindered disulfide drug conjugates
EP3365025B1 (en) 2015-10-20 2020-07-15 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
MX375569B (en) 2017-02-08 2025-03-04 Adc Therapeutics Sa PYRROLOBENZODIAZEPINES AND ANTIBODIES CONJUGATES
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PT3612537T (en) 2017-04-18 2022-08-29 Medimmune Ltd Pyrrolobenzodiazepine conjugates
ES2977788T3 (en) 2017-04-20 2024-08-30 Adc Therapeutics Sa Combination therapy with an anti-AXL antibody-drug conjugate
MX2019015042A (en) 2017-06-14 2020-08-06 Adc Therapeutics Sa DOSAGE REGIME.
DK3668874T3 (en) 2017-08-18 2022-02-14 Medimmune Ltd Pyrrolobenzodiazepine conjugates
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP7708662B2 (en) 2018-10-24 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Conjugated chemical degraders and methods of use
IL283522B2 (en) 2018-12-03 2025-03-01 Agensys Inc Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
KR102890251B1 (en) 2019-03-15 2025-11-25 메드임뮨 리미티드 Azetidobenzodiazepine dimers and conjugates comprising the same for use in the treatment of cancer
PE20231104A1 (en) 2020-07-21 2023-07-19 Genentech Inc BRM ANTIBODY CONJUGATED CHEMICAL DEGRADATION INDUCERS AND METHODS THEREOF
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN117980327A (en) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 Specific conjugation of antibodies
AR128331A1 (en) 2022-01-26 2024-04-17 Genentech Inc CHEMICAL DEGRADATION INDUCTORS CONJUGATED WITH ANTIBODIES AND METHODS OF THESE
AR128330A1 (en) 2022-01-26 2024-04-17 Genentech Inc CHEMICAL DEGRADATION INDUCERS CONJUGATED WITH ANTIBODY AND METHODS OF THESE
EP4637833A2 (en) 2022-12-23 2025-10-29 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
EP4698230A2 (en) 2023-04-17 2026-02-25 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WU D ET AL: "Characterization and Molecular Cloning of a Putative Binding Protein for Heparin-binding Growth Factors", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 25, 5 September 1991 (1991-09-05), pages 16778 - 16785, XP000887110 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840887B2 (en) 2007-09-26 2014-09-23 Genentech, Inc. Antibodies
US9284376B2 (en) 2007-09-26 2016-03-15 Genentech, Inc. Antibodies
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
MXPA03011979A (en) 2005-04-08
JP2005508144A (en) 2005-03-31
EP1517998A2 (en) 2005-03-30
CA2451465A1 (en) 2002-12-27
AU2002347428A1 (en) 2003-01-02
WO2002102235A2 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
WO2002102235A3 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2002059377A3 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2003025138A3 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2004063355A3 (en) Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2003003906A3 (en) Diagnostic and screening methods for bladder cancer
WO2002030268A3 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2004048938A3 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2002098358A3 (en) Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
WO2003008583A3 (en) Novel compositions and methods for cancer
WO2002071928A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2004048551A3 (en) Target for therapy of cognitive impairment
MXPA05013822A (en) Novel pyrrolodihydroisoquinolines useful in the treatment of cancer.
WO2006015263A3 (en) Lonidamine analogs
WO2003000012A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2005034732A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2005097185A3 (en) Irta-5 antibodies and their uses
WO2003045230A3 (en) Novel compositions and methods for cancer
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
WO2006037462A3 (en) Cancer markers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/011979

Country of ref document: MX

Ref document number: 2003504826

Country of ref document: JP

Ref document number: 2451465

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002752063

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002752063

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002752063

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)